|
|
Post by joeypotsandpans on Aug 30, 2021 10:08:15 GMT -5
Sitting here on my deck with my morning coffee. Looking forward to seeing how the day unfolds. I would love to see a close above $5.00 today. Time will tell. 39 business days to the 21st Oct. 2021.... two more trading days ends the month. $5.50 last months high. @$5.30 is point of smaller triangle break out. Let's see. It would be nice to have a strong ending of the month and have price pull up out of the consolidation. One more thing. Perhaps what we have been witnessing price and volume wise is the slow turn. A repositioning so to speak. Everyone one on Wall Street knows what we have been typing about. Consider, Wall Street rode MNKD all the way down, the slow turn of repositioning, Wall Street is going to ride MNKD all the way up now. Oh please. Feels like someone has been winding this one up...always nice when the technicals and fundamentals are aligned 😉 giphy.com/gifs/pug-dog-Aj39oEtrbojkc |
|
|
|
Post by mango on Aug 30, 2021 11:51:04 GMT -5
Our partnership with NRx may end up being bigger than anyone imaged.
NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
- NRx Has Provided Updated Data to US Food and Drug Administration (FDA) in Support of Emergency Use Authorization Request for ZYESAMI™ (aviptadil)
- NRx to Submit Breakthrough Therapy Designation to FDA for ZYESAMI™ for the Treatment of Respiratory Failure in Patients with Critical COVID-19
|
|
|
|
Post by longliner on Sept 1, 2021 9:38:06 GMT -5
|
|
|
|
Post by sellhighdrinklow on Sept 2, 2021 10:57:08 GMT -5
Link doesn't work for me. |
|
|
|
Post by longliner on Sept 2, 2021 11:06:22 GMT -5
Link doesn't work for me. That's odd. There's nothing earth shaking in it, it just rehashes the MNKD/UTHR agreement. |
|
|
|
Post by BD on Sept 2, 2021 13:29:59 GMT -5
That's twice now...the first time I click on the link I get an error page, then I go back and click on it again and I get to the article. The same sequence happened yesterday (I guess), and when it worked the second time I just went "hmmm" and forgot about it... (I run Chrome BTW)
|
|
|
|
Post by sportsrancho on Sept 2, 2021 21:28:40 GMT -5
Link doesn't work for me. Worked the first time for me on my iPhone. |
|
|
|
Post by uvula on Oct 10, 2021 17:23:05 GMT -5
This thread was started Aug 25. NRXP was a sure thing. UTHR had nothing standing in their way. Now both are involved in lawsuits. Investing is tricky, particularly in biotechs.
|
|
|
|
Post by cretin11 on Oct 11, 2021 5:22:13 GMT -5
This thread was started Aug 25. NRXP was a sure thing. UTHR had nothing standing in their way. Now both are involved in lawsuits. Investing is tricky, particularly in biotechs. Hopefully those are just temporary eclipses of our future greatness. |
|
|
|
Post by mango on Oct 11, 2021 12:28:11 GMT -5
This thread was started Aug 25. NRXP was a sure thing. UTHR had nothing standing in their way. Now both are involved in lawsuits. Investing is tricky, particularly in biotechs. It will be interesting to see how things play out for NRx and if what’s happening has any implications with our collaboration. The good news is, we haven’t investment much resources and capital towards this project yet, so if we need to pull out it’s not an issue for us. What stands in UT’s way? UT is the plaintiff in the lawsuits against Liquidia. Liquidia has a patent infringement lawsuit and trade secret theft standing in their way. |
|
|
|
Post by veritasfiliatemporis on Oct 11, 2021 15:06:15 GMT -5
"NRx Pharmaceuticals advised Relief that NRx Pharmaceuticals is funding those costs with other capital. NRx Pharmaceuticals further advised Relief in December 2020 that the formulation data provided to NRx Pharmaceuticals as part of the collaboration agreement was non-reproducible."
I read, IQVIA is supporting the cost and/or the studies to develop a stable formulation. Mannkind will support the inhale technology, NRXP drops, with very low volume, because the fast approval has vanished, and some are shorting the price quite bad ....
|
|
